Is L-carnitine effective in treating pediatric epilepsy?

Levocarnitine cannot cure pediatric epilepsy as a monotherapy; it is only used as an adjunctive treatment to help improve the clinical condition in some children. It demonstrates better efficacy in epilepsy caused by metabolic disorders, but offers limited benefit for primary (idiopathic) epilepsy. If a child experiences increased seizure frequency or worsening mental status, prompt medical consultation is essential to adjust the treatment regimen.

Pediatric epilepsy is commonly triggered by abnormal neuronal discharges in the brain and is broadly classified into two categories: primary (idiopathic) epilepsy and metabolism-related epilepsy. The core etiology of primary epilepsy lies in abnormal neurodevelopment, requiring standard antiepileptic drugs (AEDs) to modulate neuronal activity. Levocarnitine primarily functions by regulating cerebral energy metabolism and protecting neurons; however, it does not directly suppress abnormal neuronal discharges and therefore cannot replace conventional AEDs for core epilepsy management.

In clinical practice, levocarnitine is predominantly employed as an adjunctive therapy—particularly for children with carnitine deficiency or those undergoing long-term AED treatment. It helps replenish depleted carnitine stores, improves cerebral cellular metabolism, mitigates AED-related adverse effects, and may contribute to reducing seizure frequency. In cases of metabolism-related pediatric epilepsy, supplementation with levocarnitine can synergistically enhance the efficacy of primary AEDs and promote better disease stabilization.

Parents should ensure that affected children maintain adequate sleep, follow a light and nutritionally balanced diet, and engage regularly in mild physical activity—measures that collectively support stable metabolic function and minimize disease fluctuations attributable to metabolic dysregulation.